A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
A Phase II/III Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of BL-M11D1 for Injection in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Sa Xiao, PHD
- Phone Number: 15013238943
- Email: xiaosa@baili-pharm.com
Study Locations
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China
- Recruiting
- Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences
-
Principal Investigator:
- Jianxiang Wang
-
Contact:
- Jianxiang Wang
-
Principal Investigator:
- Hui Wei
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntarily sign the informed consent form and comply with the protocol requirements;
- No gender restrictions;
- Age: ≥18 years;
- Expected survival time ≥3 months;
- Newly diagnosed AML according to the World Health Organization (WHO) 2016 classification and confirmed by morphology;
- ECOG performance status score ≤2;
- Peripheral blood white blood cell count ≤25×10⁹/L before the first dose;
- Organ function levels must meet the requirements;
- For premenopausal women with childbearing potential, a pregnancy test must be performed within 7 days before starting treatment, and the serum/urine pregnancy test must be negative. Patients must not be breastfeeding; all enrolled patients (regardless of male or female) should adopt adequate barrier contraception throughout the entire treatment cycle and for 6 months after the end of treatment.
Exclusion Criteria:
- Acute promyelocytic leukemia, acute transformation of chronic myeloid leukemia;
- Previous treatment for AML;
- Participation in other interventional or observational studies;
- History of severe cardiovascular or cerebrovascular diseases within 6 months prior to screening;
- Prolonged QT interval, complete left bundle branch block, third-degree atrioventricular block, frequent and uncontrollable arrhythmia;
- Active autoimmune diseases and inflammatory diseases;
- Diagnosis of other malignancies within 5 years prior to the first dose;
- Poorly controlled hypertension;
- Grade ≥3 lung disease as defined by CTCAE v5.0, history of interstitial lung disease requiring systemic steroid therapy, etc.;
- Patients with central nervous system involvement;
- Previous organ transplantation;
- History of allergy to recombinant humanized antibodies or human-mouse chimeric antibodies, or allergy to any excipient component of BL-M11D1;
- Positive human immunodeficiency virus antibody, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection;
- Evidence of other clinically significant, poorly controlled infections requiring systemic treatment;
- Clinically symptomatic or recurrent pleural, peritoneal, pelvic, or pericardial effusion requiring drainage;
- Pregnant or lactating women;
- Within 4 weeks prior to the first dose of the study drug, subjects must not have received any live vaccines or are not expected to receive live vaccines during the study participation;
- Other conditions deemed by the investigator as unsuitable for participation in this clinical trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: BL-M11D1 in Combination with Cytarabine + Daunorubicin or Venetoclax + Azacitidine
Participants receive BL-M11D1 in Combination with Cytarabine + Daunorubicin or Venetoclax + Azacitidine for the first cycle (4 weeks).
Participants with clinical benefit could receive additional treatment for more cycles.
The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
|
Administration by intravenous infusion for a cycle of 4 weeks.
Administration in 4-week cycles.
Administration in 4-week cycles.
Administration in 4-week cycles.
Administration in 4-week cycles.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective Response Rate (ORR)
Time Frame: Up to approximately 24 months
|
ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions).
The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1.
|
Up to approximately 24 months
|
|
Composite Response Rate(CRc)
Time Frame: Up to approximately 24 months
|
CRc is defined as the proportion of patients who achieve any one of several pre-defined types of treatment response.
|
Up to approximately 24 months
|
|
Phase IIa: Recommended Phase II Dose (RP2D)
Time Frame: Up to approximately 24 months
|
The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-M11D1.
|
Up to approximately 24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disease Control Rate (DCR)
Time Frame: Up to approximately 24 months
|
The DCR is defined as the percentage of participants who has a CR, PR, or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease [PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm.
The appearance of one or more new lesions is also considered PD]).
|
Up to approximately 24 months
|
|
Treatment-Emergent Adverse Event (TEAE)
Time Frame: Up to approximately 24 months
|
TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-M11D1.
The type, frequency and severity of TEAE will be evaluated during the treatment of BL-M11D1.
|
Up to approximately 24 months
|
|
Progression-free survival (PFS)
Time Frame: Up to approximately 24 months
|
Progression-free survival (PFS) as assessed by BICR is defined as the time between the date subjects were randomized and the first observation of disease progression (based on BICR's image-based assessment) or death.
|
Up to approximately 24 months
|
|
Relapse-Free Survival (RFS)
Time Frame: Up to approximately 24 months
|
Relapse-Free Survival (RFS) is defined as the time from randomization (or from the start of treatment for non-randomized studies) until the first occurrence of disease recurrence or death from any cause.
|
Up to approximately 24 months
|
|
Cmax
Time Frame: Up to approximately 24 months
|
Maximum serum concentration (Cmax) of BL-M11D1 will be investigated.
|
Up to approximately 24 months
|
|
Tmax
Time Frame: Up to approximately 24 months
|
Time to maximum serum concentration (Tmax) of BL-M11D1 will be investigated.
|
Up to approximately 24 months
|
|
Ctrough
Time Frame: Up to approximately 24 months
|
Ctrough is defined as the lowest serum concentration of BL-M11D1 prior to the next dose will be administered.
|
Up to approximately 24 months
|
|
ADA (anti-drug antibody)
Time Frame: Up to approximately 24 months
|
Frequency of anti-BL-M11D1 antibody (ADA) will be investigated.
|
Up to approximately 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Neoplasms by Histologic Type
- Hematologic Diseases
- Leukemia, Myeloid
- Leukemia
- Hemic and Lymphatic Diseases
- Leukemia, Myeloid, Acute
- Organic Chemicals
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Nucleic Acids, Nucleotides, and Nucleosides
- Hydrocarbons
- Hydrocarbons, Cyclic
- Carbohydrates
- Polycyclic Aromatic Hydrocarbons
- Hydrocarbons, Aromatic
- Polycyclic Compounds
- Glycosides
- Cytidine
- Pyrimidine Nucleosides
- Pyrimidines
- Aza Compounds
- Nucleosides
- Ribonucleosides
- Arabinonucleosides
- Anthracyclines
- Naphthacenes
- Aminoglycosides
- Cytarabine
- Azacitidine
- Daunorubicin
- venetoclax
Other Study ID Numbers
Other Study ID Numbers
- BL-M11D1-201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.